I'm totally guessing here, but I would imagine the
Post# of 30066
Posted On: 04/09/2015 12:24:26 AM
Re: Daveludlow #19270
I'm totally guessing here, but I would imagine the answer would go something like this:
" We had originally expected those milestones to be met by the prescribed dates, however, as I'm sure you know, in business, especially in the biotechnology sector, dates are not always hard and fast.
We, as a corporation, present milestones, and dates, as estimates - that we use our best educated scientific and business prowess to keep our shareholders, and the public-at-large, informed as to the accomplishments of our labors. Obviously, when these timeframes are extended past what we originally anticipated, there is a lack of fulfillment that we experience, along with the shareholders, and more-so, the patients that would benefit from our successes.
We are dedicated to the improvement of the human condition, and continue to persevere in the maturity of diagnostic and therapeutic vehicles to improve the life of thousands, if not millions of suffering , worldwide.
From an investment point of view, we continue to navigate the scientific, regulatory, and business hurdles that are a prerequisite in any successful biotechnology business entity. Although we have been blessed with an unparalleled advisory team that has mapped out a mission statement for our company, our opportunities are in a constant state of flux. As a holding company, we must evaluate any and all opportunities as they present themselves. This causes our direction to shift, either minimally, or significantly, depending on the circumstance. All of these directional changes are in mind of their benefit to world health, and of course, our shareholders.
In closing, I'd like to thank you for not asking any questions on this conference call. I'm sure a 3rd grader, with very small balls could have figured this out for themselves, so.. you might want to invest in a mutual fund instead of a start-up biotech."
" We had originally expected those milestones to be met by the prescribed dates, however, as I'm sure you know, in business, especially in the biotechnology sector, dates are not always hard and fast.
We, as a corporation, present milestones, and dates, as estimates - that we use our best educated scientific and business prowess to keep our shareholders, and the public-at-large, informed as to the accomplishments of our labors. Obviously, when these timeframes are extended past what we originally anticipated, there is a lack of fulfillment that we experience, along with the shareholders, and more-so, the patients that would benefit from our successes.
We are dedicated to the improvement of the human condition, and continue to persevere in the maturity of diagnostic and therapeutic vehicles to improve the life of thousands, if not millions of suffering , worldwide.
From an investment point of view, we continue to navigate the scientific, regulatory, and business hurdles that are a prerequisite in any successful biotechnology business entity. Although we have been blessed with an unparalleled advisory team that has mapped out a mission statement for our company, our opportunities are in a constant state of flux. As a holding company, we must evaluate any and all opportunities as they present themselves. This causes our direction to shift, either minimally, or significantly, depending on the circumstance. All of these directional changes are in mind of their benefit to world health, and of course, our shareholders.
In closing, I'd like to thank you for not asking any questions on this conference call. I'm sure a 3rd grader, with very small balls could have figured this out for themselves, so.. you might want to invest in a mutual fund instead of a start-up biotech."
(0)
(0)